Stay updated with breaking news from Patients Sensitive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter Delivered $49.3 million in net income for the full year 2023, including $4.7...
Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential...
Amylyx Pharmaceuticals, Inc. today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis from...
- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx,...
Amylyx Pharmaceuticals, Inc. today announced that several abstracts detailing data on AMX0035 and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of...